Early Pimavanserin Use May Benefit Parkinson's Psychosis Patients

An analysis of trial data suggests that starting pimavanserin earlier in patients with Parkinson's disease psychosis could lead to better improvement in psychotic symptoms. The study indicated a potential advantage in symptom reduction for those who began treatment within six months of symptom onset. This finding offers insights into optimizing treatment strategies for this condition.